Radotinib (Supect)
Revision as of 17:18, 25 July 2017 by Warner-admin (talk | contribs) (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications")
Mechanism of action
Selective BCR-ABL1 tyrosine kinase inhibitor
Preliminary data
Chronic myelogenous leukemia
- Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. Epub 2014 Apr 4. link to original article PubMed